Good morning :)
$
₹
Incannex Healthcare Inc.

Incannex Healthcare Inc.

IXHL

NASDAQ
Asset Logo

Incannex Healthcare Inc.

IXHL

NASDAQ
$2.822.08% (-0.06)
$
₹
$2.822.08% (-0.06)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Drug Manufacturers - Specialty & Generic

Micro Cap

With a market cap of $35.4M the stock is ranked 5263

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.54
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-1.62
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 1 analyst's reports

Buy
1 analyst
Hold
0 analyst
Sell
0 analyst

Price Upside

+556.79%

Earnings Growth

+7.12%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. The company is headquartered in Melbourne, Australia.
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. The company is headquartered in Melbourne, Australia.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
77.45
77.45
1Y Return
24.91%
24.91%
Buy Reco %
80.00
80.00
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
25.63
25.63
1Y Return
47.24%
47.24%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
32.53%
32.53%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
28.86
28.86
1Y Return
22.3%
22.3%
Buy Reco %
81.25
81.25
Moderna Inc
MRNA
Moderna Inc
P/E Ratio
—
—
1Y Return
703.27%
703.27%
Buy Reco %
21.73
21.73
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 556.79% growth, versus a trailing 3-year CAGR of -9.78%.

2026
Current$2.82Baseline
Analyst Target - 1 year
Target$18.52+556.79%

All values in $

202220232024202520262027$5.34$10.35$15.36Target+556.79%
2026
Current$2.82Baseline
Analyst Target - 1 year
Target$18.52+556.79%

All values in $

Earnings Per Share Forecast

Earnings Per Share Forecast

2026
Current$-2.4Baseline
Forecast for Jun 2027
High$-2.23+7.12%
Average$-2.23+7.12%
Low$-2.23+7.12%

All values in $

20232024202520262027N/A-1.22-29.99-2.4Low+7.12%Average+7.12%High+7.12%
2026
Current$-2.4Baseline
Forecast for Jun 2027
High$-2.23+7.12%
Average$-2.23+7.12%
Low$-2.23+7.12%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-6.4
-6.5
-3.8
-12.7
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue00.010.100.0100.06000-
Net Income-9.28-6.46-7.98-3.96-3.96-35.57-6.40-6.52-3.88-12.78
Net Profit Margin--53841.66%-7324.32%-20470.49%--53398.58%----
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - Specialty & Generic

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Incannex Healthcare Inc. -0.54-
AbbVie Inc77.4550.450.54
Amgen Inc25.6318.782.45
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare IXHL with any stock or ETF
Compare IXHL with any stock or ETF
Comparing from
IXHL
ABBV
AMGN
Loading...

Frequently asked questions

  1. Incannex Healthcare Inc. (IXHL) share price today is $2.82 as of October 17, 2026 at 1:30 AM IST. The stock touched a day high of $2.92 and a day low of $2.79.

  2. Incannex Healthcare Inc. stock trades on NASDAQ under the ticker symbol IXHL.

  3. Incannex Healthcare Inc.'s market capitalization is $35.44M as of October 17, 2026 at 1:30 AM IST.

  4. Incannex Healthcare Inc.'s price-to-earnings (P/E) ratio is N/A as of October 16, 2026.

  5. Incannex Healthcare Inc.'s price-to-book (P/B) ratio is 0.54 as of October 16, 2026.

  6. Yes, You can buy Incannex Healthcare Inc. shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Incannex Healthcare Inc. shares in three steps: 1. Search Incannex Healthcare Inc. on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Incannex Healthcare Inc. trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Incannex Healthcare Inc. (IXHL) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 3.546 shares at the current price of $2.82.

Loading...